Identifying Early Signals From Emerging Public Health Events Using Natural Language Processing. [PDF]
Peterson KS +7 more
europepmc +1 more source
Tracking Motor Progression and Device‐Aided Therapy Eligibility in Parkinson's Disease
ABSTRACT Objective To characterise the progression of motor symptoms and identify eligibility for device‐aided therapies in Parkinson's disease, using both the 5‐2‐1 criteria and a refined clinical definition, while examining differences across genetic subgroups.
David Ledingham +7 more
wiley +1 more source
Knowledge structure and academic influence in lung transplantation: a systematically bibliometric analysis of highly cited documents and multi-perspective extensive review. [PDF]
Xie Y, Xing Y, Mi X, Dai Z, Pu Q.
europepmc +1 more source
Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin +2 more
wiley +1 more source
Deep learning enabled pseudonymization for preserving data privacy of financial identifiers in public documents in India. [PDF]
Roopalakshmi R, Kailas S, Sreelatha R.
europepmc +1 more source
ABSTRACT Objective This study aims to identify both fluid and neuroimaging biomarkers for CSF1R‐RD that can inform the optimal timing of treatment administration to maximize therapeutic benefit, while also providing sensitive quantitative measurements to monitor disease progression.
Tomasz Chmiela +13 more
wiley +1 more source
Substance use of older adults in gerontological social work client documents. [PDF]
Kaitala I +3 more
europepmc +1 more source
Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer +14 more
wiley +1 more source
Construction and application of knowledge graph for seed quality standard documents. [PDF]
Yang Z, He Q, Zhang J.
europepmc +1 more source

